华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600062 华润双鹤

已收盘 12-19 15:00:00

{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":20.04,"timestamp":1734591600000,"preClose":20.06,"halted":0,"volume":9325102,"delay":0,"floatShares":1027000000,"shares":1039000000,"eps":1.5905,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"12-19 15:00:00","open":19.97,"high":20.04,"low":19.8,"amount":186000000,"amplitude":0.012,"askPrice":20.04,"askSize":362,"bidPrice":20.03,"bidSize":63,"shortable":0,"etf":0,"ttmEps":1.5905,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":20.06,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":22.07,"lowLimit":18.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038894722,"pbRate":2.04,"roa":"--","roe":"12.39%","epsLYR":1.3002,"committee":-0.704626,"marketValue":20819000000,"floatMarketCap":20585000000,"peRate":12.599811,"changeRate":-0.001,"turnoverRate":0.0091,"status":1},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2492450173","title":"华润双鹤启动普瑞巴林缓释片III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2492450173","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492450173?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:17","pubTimestamp":1734599836,"startTime":"0","endTime":"0","summary":"财中社12月19日电华润双鹤 发布关于全资子公司华润双鹤利民药业(济南)有限公司普瑞巴林缓释片临床试验进展的公告。该临床试验的登记号为CTR20243987，旨在评价普瑞巴林缓释片治疗带状疱疹后神经痛的有效性和安全性。普瑞巴林缓释片为原研未进口仿制药，需进行有效性及安全性临床试验后方可申报生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219173932ab8418ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219173932ab8418ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0010","BK0185","BK0175","BK0239","BK0028","600062","BK0188"],"gpt_icon":0},{"id":"2492141848","title":"华润双鹤最新公告：普瑞巴林缓释片III期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2492141848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492141848?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:11","pubTimestamp":1734599483,"startTime":"0","endTime":"0","summary":"华润双鹤公告，公司全资子公司双鹤利民已启动普瑞巴林缓释片III期临床试验，正式展开受试者招募。该药品主要用于治疗带状疱疹后神经痛及与糖尿病周围神经病变相关的神经性疼痛。普瑞巴林缓释片为原研未进口仿制药，需进行有效性及安全性临床试验才能申报生产，已获得医学伦理委员会批件。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900028377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0239","BK1141","BK1583","BK1576","BK0010","03347","BK0175","BK0028","600062"],"gpt_icon":0},{"id":"2492939620","title":"华润双鹤：舒更葡糖钠注射液生产线通过GMP符合性检查，设计产能为700万支/年","url":"https://stock-news.laohu8.com/highlight/detail?id=2492939620","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492939620?lang=zh_cn&edition=full","pubTime":"2024-12-17 17:16","pubTimestamp":1734427000,"startTime":"0","endTime":"0","summary":"12月17日，华润双鹤发布关于通过GMP符合性检查的公告。本次药品GMP符合性检查，是舒更葡糖钠注射液上市前的首次药品GMP符合性检查，是在原有厂房基础上新建生产线。舒更葡糖钠注射液由默沙东研制开发，于2008年7月在欧盟批准上市，商品名为“Bridion”；其后分别于 2010、2015 年在日本和美国上市；于2017年4月获准在中国上市销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217171811ab7eb656&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217171811ab7eb656&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0185","BK0028","600062","BK0188","BK0175","BK0010","BK0239"],"gpt_icon":0},{"id":"2492933059","title":"华润双鹤最新公告：通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2492933059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492933059?lang=zh_cn&edition=full","pubTime":"2024-12-17 17:09","pubTimestamp":1734426595,"startTime":"0","endTime":"0","summary":"华润双鹤公告，公司近日收到北京市药品监督管理局颁发的《药品GMP符合性检查告知书》。检查范围为冻干车间小容量注射剂S生产线，设计产能为700万支/年，生产品种为舒更葡糖钠注射液。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700028723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","BK0185","BK0239","600062","BK0188","BK0010"],"gpt_icon":0},{"id":"2492933615","title":"华润双鹤(600062.SH)通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2492933615","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492933615?lang=zh_cn&edition=full","pubTime":"2024-12-17 17:02","pubTimestamp":1734426156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤 发布公告，近日，公司收到北京市药品监督管理局颁发的《药品GMP符合性检查告知书》，检查范围及相关车间、生产线：冻干车间：小容量注射剂S生产线，舒更葡糖钠注射液。公司本次通过药品GMP符合性检查，表明公司产品生产质量管理符合GMP要求，将有利于公司继续保持稳定的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。本次药品GMP符合性检查结果不会对公司业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)通过GMP符合性检查","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062","BK0175","BK0188","BK0185","BK0010","BK0028","BK0239"],"gpt_icon":0},{"id":"2491340708","title":"华润双鹤(600062.SH)部分药品在全国药品集中采购中拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2491340708","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491340708?lang=zh_cn&edition=full","pubTime":"2024-12-13 18:38","pubTimestamp":1734086311,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，2024年12月12日，公司及部分下属子公司参加了联合采购办公室(简称“联采办”)组织的第十批全国药品集中采购。公司包括舒更葡糖钠注射液在内的部分产品拟中选本次集中采购。本次药品集中采购是国家组织的第十批国家药品集中采购，采购周期中，医疗机构将优先使用本次药品集中采购中选药品，并确保完成约定采购量。本次部分拟中选药品价格较拟中选省份现销售价格有一定程度下降。本次拟中选产品确定中选、签订购销合同并实施，将有利于提高产品市场占有率，提升公司的品牌影响力，对公司未来的经营业绩产生积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)部分药品在全国药品集中采购中拟中选","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0239","600062","BK0028","BK0175","BK0185","BK0188"],"gpt_icon":0},{"id":"2490806463","title":"华润双鹤：感谢您对公司的支持！","url":"https://stock-news.laohu8.com/highlight/detail?id=2490806463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490806463?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:00","pubTimestamp":1734001237,"startTime":"0","endTime":"0","summary":"证券之星消息，华润双鹤12月12日在投资者关系平台上答复投资者关心的问题。根据公平披露原则，公司在定期报告中面向所有投资者统一披露截至报告期末的股东户数，敬请关注公司定期报告。截至2024年三季度末，公司普通股股东总数为40,648户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200031160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600062","BK0175","BK0028","BK0010","BK0188","BK0185"],"gpt_icon":0},{"id":"2490876368","title":"华润双鹤独董余顺坤短线交易获利8200元遭警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2490876368","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490876368?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:52","pubTimestamp":1733989920,"startTime":"0","endTime":"0","summary":"12月12日消息，近日，北京证监局对华润双鹤药业股份有限公司（以下简称华润双鹤）独立董事余顺坤出具警示函，其于2024年7月15日至2024年7月19日期间买入华润双鹤股票10000股、交易金额174，400元，卖出华润双鹤股票10000股、交易金额182，600元。\n　\n　　北京证监局表示，上述行为违反了《证券法》第四十四条的规定，根据《证券法》第一百七十条规定，决定对余顺坤采取出具警示函的行政监管措施。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：公司观察","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-12-12/doc-inczeuyp3012602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0185","BK0028","BK0188","600062","BK0239","BK0175","BK0010"],"gpt_icon":0},{"id":"2490280438","title":"涉违规交易 华润双鹤独董被警示","url":"https://stock-news.laohu8.com/highlight/detail?id=2490280438","media":"中国网财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490280438?lang=zh_cn&edition=full","pubTime":"2024-12-12 11:38","pubTimestamp":1733974680,"startTime":"0","endTime":"0","summary":"根据公告，华润双鹤独立董事余顺坤于近日收到中国证监会北京监管局出具的《关于对余顺坤采取出具警示函措施的决定》。经查，余顺坤担任华润双鹤独立董事期间，于2024年7月15日至2024年7月19日期间买入华润双鹤股票1万股、交易金额17万余元，卖出华润双鹤股票1万股、交易金额 18万多元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212114136a1e7f919&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212114136a1e7f919&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0239","BK0175","BK0028","BK0185","600062","BK0010"],"gpt_icon":0},{"id":"2490835923","title":"华润双鹤(600062.SH)独立董事余顺坤收到北京证监局警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2490835923","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490835923?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:17","pubTimestamp":1733908655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤 公告，公司独立董事余顺坤于近日收到中国证券监督管理委员会北京监管局出具的《关于对余顺坤采取出具警示函措施的决定》，现将相关情况公告如下：余顺坤：经查，你担任华润双鹤药业股份有限公司独立董事期间，于2024年7月15日至2024年7月19日期间买入华润双鹤股票10,000股、交易金额174,400元，卖出华润双鹤股票10,000股、交易金额182,600元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","600062","BK0010","BK0185","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2490683835","title":"华润双鹤(600062.SH)子公司药品丙戊酸钠缓释片(Ⅰ)获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490683835","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490683835?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:15","pubTimestamp":1733908530,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)公告，近日，公司控股子公司湖南省湘中制药有限公司(简称“湘中制药”)收到了国家药品监督管理局(简称“国家药监局”)颁发的丙戊酸钠缓释片(Ⅰ)(简称“该药品”)《药品注册证书》。据悉，丙戊酸钠缓释片(Ⅰ)是一种用于治疗癫痫和躁狂症的神经系统疾病药物，用于治疗全面性癫痫和部分性癫痫，既可作为单药治疗，也可作为添加治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","600062","BK0010","BK0185","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2490355978","title":"华润双鹤最新公告：控股子公司湘中制药丙戊酸钠缓释片(I)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490355978","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490355978?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:10","pubTimestamp":1733908245,"startTime":"0","endTime":"0","summary":"华润双鹤公告，公司控股子公司湖南省湘中制药有限公司收到国家药监局颁发的丙戊酸钠缓释片(Ⅰ)《药品注册证书》。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100028245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0185","BK1191","BK0010","BK0188","600062","01477","BK0239","BK0028","BK1574"],"gpt_icon":0},{"id":"2490283555","title":"华润双鹤最新公告：独立董事收到北京证监局警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2490283555","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490283555?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:10","pubTimestamp":1733908231,"startTime":"0","endTime":"0","summary":"华润双鹤公告，公司独立董事余顺坤于近日收到中国证券监督管理委员会北京监管局出具的《关于对余顺坤采取出具警示函措施的决定》。上述行为违反了《证券法》第四十四条的规定，北京监管局决定对余顺坤采取出具警示函的行政监管措施。余顺坤已深刻认识到本次短线交易的严重性，对给公司和市场带来的不良影响深表歉意，并承诺加强学习和严格遵守相关法律法规等规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100028243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0175","BK0188","BK0185","BK0010","BK0028","BK0239"],"gpt_icon":0},{"id":"2490988830","title":"华润双鹤控股子公司2.96亿元项目环评获同意","url":"https://stock-news.laohu8.com/highlight/detail?id=2490988830","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490988830?lang=zh_cn&edition=full","pubTime":"2024-12-11 09:08","pubTimestamp":1733879286,"startTime":"0","endTime":"0","summary":"每经AI快讯，“A股绿色报告”项目监控到的数据显示，华润双鹤 控股子公司湖南省湘中制药有限公司湘中制药医药原料药生产基地建设项目（一期）环评审批获同意。该项目总投资额达2.96亿元。上期A股绿色周报显示，共有10家上市公司在近期暴露了环境风险。文章来源：每日经济新闻华润双鹤控股子公司2.96亿元项目环评获同意","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211092914ab6e1ac0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211092914ab6e1ac0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","600062","BK0175","BK0028","BK0010","BK0188","BK0185"],"gpt_icon":0},{"id":"2490046825","title":"华润双鹤：独立董事余顺坤因涉嫌违反证券法律法规等违规行为被证监会出具警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2490046825","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490046825?lang=zh_cn&edition=full","pubTime":"2024-12-11 01:00","pubTimestamp":1733850042,"startTime":"0","endTime":"0","summary":"证券之星消息，12月10日华润双鹤公开信息显示，独立董事余顺坤因涉嫌违反证券法律法规,违规交易被中国证监会北京监管局出具警示函。详细违规行为如下：经查,你担任华润双鹤药业股份有限公司(以下简称华润双鹤)独立董事期间,于2024年7月15日至2024年7月19日期间买入华润双鹤股票10,000股、交易金额174,400元,卖出华润双鹤股票10,000股、交易金额182,600元。处罚决定如下：采取出具警示函的行政监管措施以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100000387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","161027","BK0188","BK0028","BK0239","BK0175","600062","BK0010"],"gpt_icon":0},{"id":"2490106216","title":"北京证监局：对华润双鹤独立董事余顺坤出具警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2490106216","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490106216?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:36","pubTimestamp":1733823404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0010","BK0239","BK0188","BK0175","BK0185","BK0028","600062"],"gpt_icon":0},{"id":"2489286362","title":"华润双鹤12月06日获主力加仓723万元 环比增加327.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489286362","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489286362?lang=zh_cn&edition=full","pubTime":"2024-12-06 15:17","pubTimestamp":1733469472,"startTime":"0","endTime":"0","summary":"12月06日, 华润双鹤股价涨2.06%，报收20.82元，成交金额2.72亿元，换手率1.28%，振幅2.75%，量比1.06。华润双鹤今日主力资金净流入723万元，上一交易日主力净流入169万元，今日环比增加327.81%。该股近5个交易日下跌2.35%，主力资金累计净流出2004万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出6093万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206151944a1d87f8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206151944a1d87f8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0185","BK0010","BK0188","600062","BK0239","BK0028"],"gpt_icon":0},{"id":"2488154956","title":"华润双鹤最新公告：控股子公司及全资子公司部分产品获得药品注册证书及药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2488154956","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488154956?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:01","pubTimestamp":1733302875,"startTime":"0","endTime":"0","summary":"华润双鹤公告，控股子公司湘中制药收到马来酸氟伏沙明片《药品注册证书》，全资子公司双鹤利民收到氯化钾注射液《药品补充申请批准通知书》。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400029330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0010","BK0188","BK0175","600062","BK0185","BK0239"],"gpt_icon":0},{"id":"2488548491","title":"华润双鹤(600062.SH)：马来酸氟伏沙明片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2488548491","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488548491?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:54","pubTimestamp":1733302489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，公司控股子公司湖南省湘中制药有限公司(简称“湘中制药”)收到了国家药品监督管理局颁发的马来酸氟伏沙明片《药品注册证书》(证书编号：2024S03052)，全资子公司华润双鹤利民药业(济南)有限公司(简称“双鹤利民”)收到了国家药监局颁发的氯化钾注射液《药品补充申请批准通知书》(通知书编号：2024B05632)。马来酸氟伏沙明片是一种SSRIs类抗抑郁药，用于治疗各种抑郁症和强迫症。氯化钾注射液临床用于治疗和预防低钾血症，适用于无法口服补钾时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：马来酸氟伏沙明片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0188","BK0028","BK0239","BK0175","600062","BK0010"],"gpt_icon":0},{"id":"2488628667","title":"华润双鹤12月02日遭主力抛售2009万元 环比增加112.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488628667","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488628667?lang=zh_cn&edition=full","pubTime":"2024-12-02 15:19","pubTimestamp":1733123984,"startTime":"0","endTime":"0","summary":"12月02日, 华润双鹤股价涨0.42%，报收21.41元，成交金额2.73亿元，换手率1.25%，振幅2.16%，量比1.09。华润双鹤今日主力资金净流出2009万元，连续3日净流出，上一交易日主力净流出945万元，今日环比增加112.59%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为63.64%，平均跌幅为2.02%。该股近5个交易日上涨2.39%，主力资金累计净流出4508万元；近20日主力资金累计净流入9182万元，其中净流入天数为8日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202153256abef0642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202153256abef0642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600062","BK0175","BK0188","BK0185","BK0010","BK0028","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","stockEarnings":[{"period":"1week","weight":-0.0462},{"period":"1month","weight":-0.0773},{"period":"3month","weight":-0.027},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.0917},{"period":"ytd","weight":0.0982}],"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","perCapita":"25271股","boardName":"医药制造业","registeredCapital":"103889万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":"　　华润双鹤药业股份有限公司是主营业务为慢病业务、专科业务和输液业务三大业务。主要产品包括复方利血平氨苯蝶啶片(0号)、胞磷胆碱钠片(诺百益)、苯磺酸氨氯地平片(压氏达)、丙戊酸镁缓释片(神泰)、格列喹酮片(糖适平)、软袋(含直软)、内封式聚丙烯输液。","serverTime":1734636222295,"listedPrice":6.69,"stockholders":"40648人(较上一季度减少7.63%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}